Literature DB >> 1540337

Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy.

T L Whiteside1, L M Jost, R B Herberman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1540337     DOI： 10.1016/1040-8428(92)90063-v

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  12 in total

1.  T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.

Authors:  W M Mulder; E Bloemena; M J Stukart; J A Kummer; J Wagstaff; R J Scheper
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

2.  High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.

Authors:  E Roussel; M C Gingras; E A Grimm; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

3.  Expression of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in non-small-cell lung carcinoma.

Authors:  A J Staal-van den Brekel; F B Thunnissen; W A Buurman; E F Wouters
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

4.  Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies.

Authors:  M J Flens; W M Mulder; H Bril; M B von Blomberg van de Flier; R J Scheper; R A van Lier
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

5.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

Review 6.  The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer.

Authors:  T H Stewart; S C Tsai
Journal:  Clin Exp Metastasis       Date:  1993-07       Impact factor: 5.150

7.  Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.

Authors:  D Risin; E S Kleinerman; Y Umezu; R P Pizzini; C M Balch; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

8.  Cytokine production and expression of adhesion molecules and integrins in tumor infiltrating lymphomononuclear cells of non-small cell carcinomas of the lung.

Authors:  D Vitolo; M B Palmieri; L P Ruco; E Rendina; G Bonsignore; C D Baroni
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

9.  T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.

Authors:  J Shilyansky; M I Nishimura; J R Yannelli; Y Kawakami; L S Jacknin; P Charmley; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 10.  Role of human natural killer cells in health and disease.

Authors:  T L Whiteside; R B Herberman
Journal:  Clin Diagn Lab Immunol       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.